Related Experiment Videos
Topical cannabinoid antinociception: synergy with spinal sites
Ahmet Dogrul1, Husamettin Gul, Ahmet Akar
1Department of Pharmacology, Gulhane Military Medical Academy, 06018 Ankara, Turkey. dogrula@gata.edu.tr
Pain
|September 23, 2003
Summary
Topical application of WIN 55, 212-2, a cannabinoid agonist, demonstrated dose-dependent pain relief in mice by activating peripheral CB(1) receptors. This topical treatment synergized with spinal cannabinoid action, suggesting potential for localized pain management without central side effects.
Area of Science:
- Pharmacology
- Neuroscience
- Pain Research
Background:
- Cannabimimetic compounds are known for central analgesic effects.
- The role of peripheral cannabinoid receptors in pain perception requires further clarification.
Purpose of the Study:
- To assess the topical antinociceptive effects of WIN 55, 212-2, a mixed CB(1) and CB(2) receptor agonist.
- To investigate the involvement of CB(1) receptors in the topical analgesic action.
- To explore the interaction between peripheral and spinal cannabinoid systems in pain modulation.
Main Methods:
- Topical application of WIN 55, 212-2 to mouse tails.
- Tail-flick test to measure antinociception.
- Administration of CB(1) receptor antagonist AM 251.
- Intrathecal (i.th.) administration of WIN 55, 212-2.
Main Results:
- Topical WIN 55, 212-2 produced dose-dependent antinociception localized to the application site.
- The antinociceptive effect was blocked by topical AM 251, confirming CB(1) receptor involvement.
- Synergistic antinociception was observed when topical and ineffective intrathecal doses of WIN 55, 212-2 were combined.
Conclusions:
- Topical cannabinoid agonists, acting via peripheral CB(1) receptors, can produce localized analgesia.
- A synergistic interaction exists between peripheral and spinal cannabinoid pathways for pain relief.
- Topical cannabinoid administration offers a potential strategy for pain management with reduced central side effects.